Read + Share
Amedeo Smart
Independent Medical Education
Hofman MS, Emmett L, Sandhu S, Iravani A, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021;397:797-804.PMID: 33581798
Email
LinkedIn
Facebook
Twitter
Privacy Policy